Weight Loss with Tyrosinaemia Type 1 in South Africa

Hereditary tyrosinaemia type 1 (HT1) is an autosomal recessive disorder caused by deficiency of fumarylacetoacetate hydrolase (FAH) — the final enzyme in the tyrosine degradation pathway. Without FAH, toxic metabolites (fumarylacetoacetate, maleylacetoacetate, and especially succinylacetone) accumulate, causing progressive liver failure, renal tubular disease, peripheral neuropathy, and hepatocellular carcinoma risk.

The introduction of NTBC (nitisinone / Orfadin) in the 1990s transformed HT1 from a condition with near-certain liver failure in childhood to one with near-normal life expectancy — provided NTBC is taken consistently and the diet is maintained. NTBC blocks the pathway upstream of FAH, preventing toxic metabolite accumulation. However, NTBC causes plasma tyrosine levels to rise sharply, so strict dietary restriction of both phenylalanine and tyrosine remains essential.

In South Africa, HT1 is diagnosed through the national newborn screening programme (succinylacetone on dried blood spot) and managed at metabolic centres including Steve Biko Academic Hospital (Pretoria), Charlotte Maxeke Johannesburg Academic Hospital, and Red Cross War Memorial Children's Hospital (Cape Town). NTBC is registered in South Africa and available under Prescribed Minimum Benefit (PMB) classification as a rare metabolic disorder.

Why HT1 Makes Weight Management Complex

1. Severely restricted natural protein intake

Phenylalanine and tyrosine are found in virtually all natural proteins. HT1 dietary management prescribes very low natural protein — typically 1–2 g/kg/day from natural foods for adults, far below the 1.6–2.2 g/kg recommended for active weight loss in the general population. The protein requirement is instead met through tyrosine-free, phenylalanine-free amino acid supplements.

This creates several weight-management challenges:

• High-natural-protein foods (meat, chicken, eggs, dairy, legumes, fish) are strictly controlled — popular high-protein weight-loss approaches cannot be applied
• The amino acid supplements used are typically low in energy and must be consumed in divided doses throughout the day
• Standard protein powders (whey, casein, soy, pea, hemp) contain phenylalanine and tyrosine — they are absolutely contraindicated
• Very low natural protein intake can reduce satiety — careful planning of low-protein, high-fibre foods is needed to manage hunger

2. NTBC-related plasma tyrosine elevation

NTBC inhibits 4-hydroxyphenylpyruvate dioxygenase (HPPD), so dietary tyrosine can no longer be degraded — it accumulates in blood and tissues. Elevated plasma tyrosine causes:

• Keratopathy — painful corneal crystals requiring urgent ophthalmology review
• Skin lesions (hyperkeratosis of palms and soles in severe cases)
• Potential neurodevelopmental effects at very high levels

This is why strict dietary phenylalanine AND tyrosine restriction is non-negotiable even for adults who feel well. Any weight-loss plan that increases natural protein consumption risks pushing plasma tyrosine to dangerous levels.

3. Liver disease and its metabolic consequences

Even on NTBC, many HT1 patients have some degree of liver fibrosis, cirrhosis, or early hepatocellular carcinoma detected on surveillance. Liver dysfunction affects:

• Glycogen storage and glucose homeostasis — blood sugar swings are common
• Clotting factor synthesis — bruising and bleeding risk with very vigorous exercise
• Drug and supplement metabolism
• Ascites and peripheral oedema — fluid weight masks true fat loss on the scale

Anyone with established liver disease should discuss exercise intensity and caloric restriction with their hepatologist before starting any weight-loss programme.

4. Renal tubular dysfunction (Fanconi syndrome)

Before NTBC treatment or in poorly controlled HT1, the kidney's proximal tubule is damaged — leading to urinary loss of phosphate, glucose, amino acids, and bicarbonate (Fanconi syndrome). Even on NTBC, some patients retain residual tubular dysfunction. This affects:

• Rickets / osteomalacia from phosphate wasting — bone pain and fracture risk with high-impact exercise
• Hypokalaemia (low potassium) — muscle weakness, cramps, cardiac arrhythmia risk
• Electrolyte management complexity during increased exercise sweating

Safe Caloric Deficit for HT1

The metabolic risks of caloric restriction in HT1 are primarily driven by catabolism. When the body is in energy deficit, it mobilises stored glycogen first, then fat, but also — especially with insufficient amino acid supplement intake — muscle protein. Muscle protein breakdown releases all amino acids including phenylalanine and tyrosine, raising plasma levels even without any change in dietary intake. This is the same risk seen in other aminoacidopathies such as phenylketonuria and homocystinuria.

Practical safe deficit rules for HT1:

1. Never skip amino acid supplement doses during a diet — this is the primary buffer against catabolism
2. Take amino acid supplement before exercise as well as at regular meal times
3. Ensure adequate total energy from carbohydrates and fats to meet baseline requirements before restricting
4. Monitor plasma phenylalanine and tyrosine every 4–6 weeks when making dietary changes
5. Stop restriction and consult your metabolic dietitian immediately if plasma tyrosine rises above your individual target range

Foods That Work Well for Weight Loss in HT1

With natural protein strictly limited, successful weight management in HT1 relies on foods that are naturally low in protein but filling and nutritious:

Foods to approach carefully (higher natural protein)

Exercise Guidance for HT1

Exercise is beneficial in HT1 and does not need to be avoided — but the choice of exercise should account for individual complications:

Generally safe options

• Walking, cycling, swimming — low-impact, sustained aerobic activity
• Resistance training with moderate weights (builds metabolically active muscle, supports insulin sensitivity)
• Yoga, Pilates, stretching

Modify or avoid if complications are present

• Liver disease / coagulopathy: Avoid contact sports, high-impact activities, or heavy lifting that significantly raises intra-abdominal pressure until hepatologist clears
• Renal tubular disease / osteomalacia: Avoid high-impact weight-bearing exercise (running, jumping) until bone density and phosphate levels are normalised
• Peripheral neuropathy: Balance work (swimming, cycling) preferred over activities requiring fine proprioception
• Keratopathy: Wear UV-protective wraparound sunglasses during outdoor exercise — UV exposure may worsen corneal tyrosine crystal deposits

Exercise and the amino acid supplement

Exercise-induced catabolism is the same risk as dietary restriction. Take your amino acid supplement within 30 minutes before exercise to supply substrate and blunt muscle protein breakdown. Do not train fasted.

Monitoring Progress in HT1

Standard scale weight is a useful but incomplete measure. Track:

• Plasma phenylalanine and tyrosine every 4–6 weeks during active weight loss
• Plasma succinylacetone at regular metabolic clinic visits (NTBC efficacy marker)
• Liver ultrasound / AFP as per hepatology surveillance protocol (HCC monitoring)
• Renal function: serum creatinine, phosphate, bicarbonate, urine protein
• Body composition (DEXA): distinguishes fat mass from muscle mass loss and assesses bone density — especially important if renal tubular disease has been present
• Energy levels and strength as clinical proxy for catabolism

Working with Your SA Metabolic Team

HT1 dietary management requires a specialist metabolic dietitian with aminoacidopathy experience — not a general weight-loss dietitian. Any caloric reduction plan must be reviewed by your metabolic team before implementation. Your amino acid supplement prescription and phenylalanine/tyrosine allowance will need to be recalculated at the new energy target.

Key SA contacts and resources:

• Association for Inherited Metabolic Disorders in South Africa (AIMDS) — patient support
• Metabolic dietitian at your specialist centre (Steve Biko, Charlotte Maxeke, Red Cross)
• NTBC / Orfadin is registered and available under medical aid PMB rules — ensure your scheme has it pre-authorised
• Succinylacetone monitoring available through National Health Laboratory Service (NHLS)